Lonza Group AG is the world's largest contract development and manufacturing organisation (CDMO) for the pharmaceutical and biotech industries, with roughly CHF 6.6 billion in 2024 revenue.
The company manufactures active pharmaceutical ingredients (APIs), biologics (monoclonal antibodies, cell and gene therapies), and dosage forms for clients including Moderna, Roche, Pfizer, and most of the global top 20 pharma companies.
Founded in 1897 in Visp, Canton Valais, as an electrochemicals company, Lonza pivoted to fine chemicals in the post-war period and to pharmaceutical contract manufacturing in the 1990s. The modern group is Basel-headquartered, with its largest manufacturing sites at Visp (Switzerland), Portsmouth (New Hampshire), Singapore, and Nansha (China).
The listed entity Lonza Group AG is a Swiss Aktiengesellschaft registered in Canton Basel-Stadt and listed on SIX under ticker LONN. Lonza is a Swiss-only primary listing with an OTC ADR programme for US institutional access - the same structure as Nestle and Zurich Insurance.
Lonza is the leading worked example of how Switzerland's regulatory, tax, and industrial-cluster stack supports contract pharmaceutical manufacturing at global scale. Three structural features explain why a CDMO of Lonza's size is Swiss-domiciled rather than Irish, Singaporean, or US-domiciled.
First, the Swiss patent-box regime under TRAF (2020) reduces cantonal tax on income from qualifying patents and manufacturing processes to as low as 9-11% depending on canton. For a CDMO, a meaningful share of revenue is linked to manufacturing process patents and know-how that qualify for the patent box.
Canton Basel-Stadt offers one of the more generous patent-box implementations among Swiss cantons, which is why Lonza has stayed in Basel rather than redomiciling to Zug (where the patent-box is similar but the pharma cluster is thinner).
Second, Swissmedic (the Swiss drug regulator) and the EMA have a mutual recognition agreement that gives Swiss-licensed manufacturing sites direct access to EU markets without duplicate licensing. US FDA inspections at Swiss sites are also routine. A Swiss-headquartered CDMO carries regulatory friction close to zero across its three largest customer geographies.
A Singapore or Irish CDMO must run additional regulatory overlays.
Third, Basel-Stadt's labour pool is one of the deepest pharma-specific talent clusters globally. A new CDMO startup in Basel can hire process engineers, quality specialists, and regulatory affairs staff at scale in a way that is structurally impossible in Zug or Zurich.
For Lonza's 19,000 employees, roughly a third sit in Visp and Basel, which keeps the company in Basel even though Zug offers lower headline tax rates.
Contract Development and Manufacturing Organisation - a company that manufactures pharmaceutical products on behalf of other pharma and biotech companies under contract. Lonza is the largest CDMO globally.
Swiss pharma cluster depth, proximity to Roche and Novartis as anchor customers, Swissmedic-EMA mutual recognition, and Basel-Stadt's patent-box-friendly tax regime. The combination is unmatched outside Ireland.
No. Lonza maintains a SIX-only primary listing (LONN) with OTC ADRs for US investors. Capital raising has historically been Swiss-franc debt and private placements rather than US equity issuance.
Lonza manufactured mRNA-1273 (COVID-19 vaccine) for Moderna at the Visp facility under a multi-year contract signed in 2020. The contract has been partially wound down as vaccine demand normalised.
